

MD Snapshot-Prescribing Educational Resource

- 1. What are the short and long-term risks and implications of antimicrobial use (AMU) and antimicrobial-resistant organisms (AROs)?
 - Adverse effects and outcomes of antibiotics range from less to very serious and include: digestive effects, fungal/yeast infections, drug interactions, photosensitivity to allergic reactions, Stevens Johnson syndrome, QT interval prolongation, C. difficile infections and tendonitis.
 - C. difficile infections and related expenses cost the healthcare system more than \$280 million per year (2021 data for Canada).^{kk}
 - Increased emergency department visits: at least 16% are due to AMU-related adverse drug reactions, e.g., severe skin reactions, QT interval prolongation, etc.^k
 - AROs lead to prolonged symptom duration, increased treatment failure rates, increased deaths and longer hospitalization stays. ^{a,b,c}
 - Imbalance in gut biome, which can lead to metabolic, immunologic and developmental disorders, e.g., asthma, epilepsy, obesity, type 2 diabetes and colorectal adenoma.
 - Antimicrobial resistance (AMR) has a social impact: decreased recreation and travel, quality of life and trust in the healthcare system, as well as increased isolation and discrimination.^d
 - AMR costs the Canadian healthcare system at least \$1.4 billion annually, not including costs of lost productivity and income (based on 2018 data).^d
 - Inadequate voluntary actions may result in the implementation of more powerful regulatory, fiscal and legislative policies that may be concerning to some.^g

2. What does the data say about the extent and appropriateness of antibiotic prescribing?

- According to the most recent Tracked Prescription Program report, <u>TPP Alberta Antibiotic</u> <u>Prescription Atlas 2020</u>, approximately 2 million antibiotic prescriptions were dispensed to 1.1 million unique patients in the previous year.
- Prescriptions were written by more than 17,000 prescribers for a rate of 431 prescriptions/1,000 population. Seventy-eight percent (78%) of oral antibiotics were prescribed by physicians.^h
- Over 90% of all human antimicrobial consumption occurs in the outpatient setting.ⁱ
- At least 26% of infections are resistant to the drugs used to treat them.^j
- Over 15% of infectious disease encounters in a Canadian primary care setting resulted in an unnecessary antibiotic prescription. Almost one-quarter of all antibiotic prescriptions were written for conditions where they are never or rarely indicated.^k
- Inappropriate antibiotic prescribing remains common in Canada estimated at up to 50% of prescriptions for respiratory infections.¹
- While evidence-based strategies to improve antimicrobial use have been identified in hospital settings, few have been implemented in primary care.





3. What are the drivers of inappropriate AMU?

The largest modifiable driver of resistance is antibiotic use.^k

Some factors that drive antimicrobial misuse in primary care are:1,m,k

- The lack of a long-term clinical relationship between the patient and their healthcare provider.
- Miscommunications and misunderstandings.
- Inadequate access to specialized skills and knowledge (e.g., infectious disease-trained physician or pharmacist, microbiologist).
- Limited availability of evidence-based treatment guidelines, based on current and local resistance patterns.
- Disjointed computer systems, which hinder sharing of patient-level information (e.g., allergy history, recent antimicrobial use, and laboratory and microbiology data) and population-level data (e.g., prescribing trends, up-to-date resistance patterns).
- Fewer opportunities for targeted (i.e., narrow) antimicrobial therapy, as microbiological sampling in many community-based infections is either impractical or less likely to produce meaningful results.
- A lack of cost-effective, rapid, point-of-care diagnostic tools to help healthcare professionals differentiate between viral, bacterial, and non-infectious causes of symptoms for use when thorough history-taking, physical examination and clinical assessment are inconclusive.
- Limited ability to closely follow patients given busy practices, resulting in unnecessary prescribing and longer than recommended treatment courses.
- Lack of impetus to challenge ill-defined beta-lactam allergies, resulting in increased use of broad-spectrum alternatives.
- Pressure to prescribe an antimicrobial due to real or perceived patient expectation, lack of patient knowledge about appropriate AMU, parental anxiety, need to return to work, or clinician's desire to "do something".
- Limited time for management of patient expectations and complete discussion of likely risks and benefits of therapy.
- Increased risk for inadvertent or intentional patient self-administration of therapy.

4. What actions can prescribers take to help address AMR?

- A commitment to following appropriate prescribing guidelines, e.g., posting commitment indicators in waiting and examination rooms to help manage patient expectations.
- Completing in-depth patient histories, physical examinations and clinical assessments.
- Using narrow-spectrum antibiotics instead of broad-spectrum to cause the least amount of collateral damage.
- Using oral instead of injectable antibiotics whenever possible.





- Prescribing the shortest duration of therapy.
- Practicing and encouraging infection prevention.
- Not avoiding beta-lactams without a thorough allergy assessment.¹
- Clinical decision support, either computerized or paper-based, to provide non-antimicrobial recommendations when appropriate, with or without a requirement to justify antimicrobial prescription.^{1,t}
- Communication skills training to improve the effectiveness and clarity of dialogue between patients and healthcare professionals.^{1,v}
- Educational campaigns, both for healthcare professionals and general public awareness, when used in combination with other strategies.^{1,w,x}
- If appropriate, delayed prescribing or watchful waiting strategies for certain infections (in limited circumstances).^{1,o,p,q,r,jj}

Sorry, but no amount of antibiotic will get rid of your cold.[⊥]

5. What are some clinical guidelines and references to help guide AMU?

Examples include:

Accelerating Change Transformation Team (Alberta Medical Association)

Guideline Central: Infectious Diseases

Bugs & Drugs

Infection Prevention and Control (Alberta Health Services)

Canadian Guidelines on Sexually Transmitted Infections (Health Canada)

TPP Alberta Antibiotic Prescription Atlas 2020

NB Antimicrobial Treatment Guidelines for Common Infections

Choosing Wisely Canada

Antimicrobials – Handle with Care

When Antibiotics Fail (poster)





References

- 1. Antimicrobial Stewardship in Primary Care Continuing Education Program, School of Pharmacy, University of Waterloo
- a. Friedman N, Temkin E, Carmeli Y. The negative impact of antibiotic resistance. *Clinical Microbiology and Infection*. 2016;22(5):416–422. doi:10.1016/j.cmi.2015.12.002.
- b. de Kraker M, Davey P, Grundmann H. Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in Europe. *PLoS Med.* 2011;8(10):e1001104. doi:10.1371/journal.pmed.1001104.
- c. van Hecke O, Wang K, Lee J, Roberts N, Butler C. Implications of Antibiotic Resistance for Patients' Recovery From Common Infections in the Community: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*. 2017;65(3):371–382. doi:10.1093/cid/cix233.
- d. When Antibiotics Fail (one pager) <u>https://cca-reports.ca/wp-content/uploads/2018/10/One-Pager_EN.pdf</u>
- e. Meeker D, Knight TK, Friedberg MW, Linder JA, Goldstein NJ, Fox CR, Rothfeld A, Diaz G, Doctor JN. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. JAMA Intern Med. 2014 Mar;174(3):425-31. doi: 10.1001/jamainternmed.2013.14191. PMID: 24474434; PMCID: PMC4648560. https://pubmed.ncbi.nlm.nih.gov/24474434/
- f. When Antibiotics Fail (full report) https://cca-reports.ca/wp-content/uploads/2018/10/When-Antibiotics-Fail-1.pdf
- g. Van Katwyk SR, Grimshaw JM, Hoffman SJ. Ten Years of Inaction on Antimicrobial Resistance: An Environmental Scan of Policies in Canada from 2008 to 2018. *Healthc Policy*. 2020;15(4):48-62. doi:10.12927/hcpol.2020.26224 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294451/
- h. Ellehoj E, Eurich DT, Gilani F, Smilski K, Jess E, Ellehoj ER, McDermott C, Samanani S. TPP Alberta Antibiotic Prescription Atlas 2019. Edmonton, Alberta: The College of Physicians & Surgeons of Alberta; 2021. 27 p.
- i. <u>Choosing Wisely Canada https://choosingwiselycanada.org/campaign/antibiotics/</u>
- j. Council of Canadian Academies, 2019. When Antibiotics Fail. Ottawa (ON): The Expert Panel on the Potential Socio-Economic Impacts of Antimicrobial Resistance in Canada, Council of Canadian Academies. When Antibiotics Fail: The growing cost of antimicrobial resistance in Canada
- <u>Schwartz, K, et al. Unnecessary antibiotic prescribing in a Canadian primary care setting: a descriptive analysis using routinely collected electronic medical record data. Apr 2020, 8 (2) E360-E369:</u> DOI:10.9778/cmaj0.201910175 https://www.cmaj0pen.ca/content/8/2/E360
- I. <u>Antibiotic Awareness Week Canada campaign https://antibioticawareness.ca/</u>
- m. Garau J, Nicolau D, Wullt B, Bassetti M. Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance. *J Glob Antimicrob Resist.* 2014;2(4):245-253. doi:10.1016/j.jgar.2014.08.002
- n. Government of Canada. *Tackling Antimicrobial Resistance And Antimicrobial Use: A Pan-Canadian Framework For Action*; 2017. <u>https://www.canada.ca/content/dam/hc-sc/documents/services/publications/drugs-health-products/tackling-antimicrobial-resistance-use-pan-canadian-framework-action.pdf</u>.
- o. <u>Choosing Wisely Canada Delayed Prescription</u><u>https://choosingwiselycanada.org/wp-</u> <u>content/uploads/2018/10/Delayed-Prescription-EN-.pdf</u>
- p. de la Poza Abad M, Mas Dalmau G, Moreno Bakedano M et al. Prescription strategies in acute uncomplicated respiratory infections. JAMA Intern Med. 2016;176(1):21–29. doi:10.1001/jamainternmed.2015.7088
- q. Chao J, Kunkov S, Reyes L, Lichten S, Crain E. Comparison of two approaches to observation therapy for acute otitis media in the emergency department. *Pediatrics*. 2008;121(5):e1352–e1356. doi:10.1542/peds.2007–2278
- r. Spurling G, Del Mar C, Dooley L, Foxlee R, Farley R. Delayed antibiotic prescriptions for respiratory infections. *Cochrane Database Syst Rev.* 2017;9:CD004417. doi:10.1002/14651858.cd004417.pub5
- s. Meeker D, Knight T, Friedberg M et al. Nudging guideline-concordant antibiotic prescribing. *JAMA Intern Med.* 2014;174(3):425. doi:10.1001/jamainternmed.2013.14191





- t. Meeker D, Linder J, Fox C et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices. *JAMA*. 2016;315(6):562–570. doi:10.1001/jama.2016.0275
- u. Hallsworth M, Chadborn T, Sallis A et al. Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial. *Lancet.* 2016;387(10029):1743–1752. doi:10.1016/s0140-6736(16)00215-4
- v. Legare F, Labrecque M, Cauchon M, Castel J, Turcotte S, Grimshaw J. Training family physicians in shared decision-making to reduce the overuse of antibiotics in acute respiratory infections: a cluster randomized trial. *CMAJ*. 2012;184(13):E726–E734. doi:10.1503/cmaj.120568
- Butler C, Simpson S, Dunstan F et al. Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial. *BMJ.* 2012;344:d8173– d8173. doi:10.1136/bmj.d8173
- x. Cross E, Tolfree R, Kipping R. Systematic review of public-targeted communication interventions to improve antibiotic use. *J Antimicrob Chemother*. 2016;72(4):975–987. doi:10.1093/jac/dkw520
- y. <u>Choosing Wisely Canada</u> <u>https://choosingwiselycanada.org/wp-content/uploads/2018/10/Choosing-</u> <u>Wisely-AAW-Sorry-Poster-EN-CFPC.pdf</u>
- z. <u>https://pubmed.ncbi.nlm.nih.gov/32936884/</u>
- aa. Public Health Ontario. *Antimicrobial Stewardship Programs (Asps) Metrics Examples.* 2017:1-12. https://www.publichealthontario.ca/en/eRepository/ASP_Metrics_Examples.pdf.
- bb. Accreditation Canada. *Required Organizational Practices 2012*. Ottawa; 2012.
- cc. Davey P, Marwick C, Scott C et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev.* 2017;(2):1–368. doi:10.1002/14651858.cd003543.pub4
- dd. <u>Grant, Jennifer. This Changed my Practice. University of British Columbia, Faculty of Medicine UBC CPD.</u> <u>September6, 2017. http://thischangedmypractice.com/penicillin-allergy/</u>
- ee. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: An updated practice parameter. *Ann Allergy Asthma Immunol.* 2010;105(4):259–273. doi:10.1016/j.anai.2010.08.002
- ff. Stember R. Prevalence of skin test reactivity in patients with convincing, vague, and unacceptable histories of penicillin allergy. *Allergy Asthma Proc.* 2005;26(1):59–64.
- gg. Penicillin Allergy FAQ. The American Academy of Allergy, Asthma & Immunology. https://www.aaaai.org/conditions-and-treatments/library/allergy-library/penicillin-allergy-faq.
- hh. Schiavino D, Nucera E, De Pasquale T et al. Delayed allergy to aminopenicillins: Clinical and immunological findings. *Int J Immunopathol Pharmacol.* 2006;19(4):831–840. doi:10.1177/039463200601900412
- ii. Pichichero M. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. *Pediatrics*. 2005;115(4):1048–1057. doi:10.1542/peds.2004-1276
- jj. Rowe, TA, Linder JA. Delayed Antibiotic Prescriptions in Ambulatory Care Reconsidering a Problematic Practice <u>https://broomedocs.com/wp-</u> content/uploads/2020/10/10.1001@jama.2020.2325.pdf
- kk. Levy AR, Szabo SM, Lozano-Ortega G, et al. Incidence and Costs of Clostridium difficile Infections in Canada. *Open Forum Infect Dis.* 2015;2(3):ofvo76. Published 2015 Jun 3. doi:10.1093/ofid/ofvo76 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503917/

